MCID: PNT038
MIFTS: 50

Peanut Allergy

Categories: Immune diseases

Aliases & Classifications for Peanut Allergy

MalaCards integrated aliases for Peanut Allergy:

Name: Peanut Allergy 12 15
Allergy to Peanuts 12 73
Peanut Allergic Reaction 12
Peanut Hypersensitivity 44
Allergies Peanut 55

Classifications:



External Ids:

Disease Ontology 12 DOID:4378
MeSH 44 D021183
SNOMED-CT 68 91935009
UMLS 73 C0559470

Summaries for Peanut Allergy

Disease Ontology : 12 A food allergy that is an allergy or hypersensitivity to dietary substances from peanuts causing an overreaction of the immune system which in a small percentage of people may lead to severe physical symptoms.

MalaCards based summary : Peanut Allergy, also known as allergy to peanuts, is related to food allergy and dermatitis. An important gene associated with Peanut Allergy is FLG (Filaggrin), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Nicotine and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and t cells, and related phenotypes are immune system and respiratory system

Wikipedia : 76 Peanut allergy is a type of food allergy to peanuts. It is different from tree nut allergies. Physical... more...

Related Diseases for Peanut Allergy

Diseases related to Peanut Allergy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 165)
# Related Disease Score Top Affiliating Genes
1 food allergy 30.4 FLG IFNG IL10 IL13
2 dermatitis 30.3 CCL22 FLG IFNG IGHE IL13
3 esophagitis, eosinophilic, 1 30.1 FLG IL13
4 autoimmune disease 29.9 HLA-DQB1 HLA-DRB1 IFNG IL10
5 asthma 29.6 CCL22 FLG HLA-DQB1 HLA-DRB1 IFNG IGHE
6 allergic hypersensitivity disease 29.5 CCL22 IFNG IGHE IL10 IL13
7 dermatitis, atopic 29.5 CCL22 CXCL10 FLG IFNG IGHE IL10
8 beryllium disease 10.2 HLA-DQB1 HLA-DRB1
9 limbic encephalitis with lgi1 antibodies 10.2 HLA-DQB1 HLA-DRB1
10 refractory celiac disease 10.2 HLA-DQB1 IFNG
11 exercise-induced anaphylaxis 10.2 FLG IGHE
12 narcolepsy 2 10.2 HLA-DQB1 HLA-DRB1
13 autoimmune polyglandular syndrome type 3 10.2 HLA-DQB1 HLA-DRB1
14 cardiac sarcoidosis 10.2 HLA-DQB1 IFNG
15 hypersomnia 10.2 HLA-DQB1 HLA-DRB1
16 berylliosis 10.2 HLA-DRB1 IFNG
17 eczema herpeticum 10.2 FLG IFNG
18 metal allergy 10.2 HLA-DQB1 HLA-DRB1
19 lichen planopilaris 10.2 HLA-DQB1 HLA-DRB1
20 staphylococcal toxic shock syndrome 10.2 IFNG IGHE
21 type ii mixed cryoglobulinemia 10.2 HLA-DQB1 HLA-DRB1
22 narcolepsy 1 10.2 HLA-DQB1 HLA-DRB1
23 eosinophilia-myalgia syndrome 10.2 HLA-DRB1 IFNG
24 lichen sclerosus 10.2 HLA-DQB1 HLA-DRB1
25 whipple disease 10.2 HLA-DQB1 HLA-DRB1
26 pityriasis rosea 10.2 HLA-DQB1 HLA-DRB1
27 african tick-bite fever 10.2 IFNG IL13
28 pediatric multiple sclerosis 10.2 HLA-DQB1 HLA-DRB1
29 central nervous system vasculitis 10.2 HLA-DRB1 IFNG
30 microscopic colitis 10.2 HLA-DQB1 HLA-DRB1
31 cephalosporin allergy 10.2 IFNG IL10
32 histoplasmosis 10.2 HLA-DRB1 IFNG
33 chronic inflammatory demyelinating polyradiculoneuropathy 10.2 HLA-DRB1 IFNG
34 osteonecrosis of the jaw 10.2 HLA-DQB1 HLA-DRB1
35 hyperlucent lung 10.2 IFNG IL10
36 strongyloidiasis 10.2 IFNG IL13
37 sporotrichosis 10.2 IFNG IL10
38 ascaris lumbricoides infection 10.2 IFNG IL13
39 cytomegalovirus retinitis 10.2 HLA-DQB1 IFNG
40 baylisascariasis 10.2 IFNG IL10
41 juvenile myasthenia gravis 10.2 HLA-DRB1 IL10
42 lichen disease 10.2 FLG IFNG
43 chronic graft versus host disease 10.2 IFNG IL10
44 hyper ige syndrome 10.2 IFNG IGHE
45 microscopic polyangiitis 10.2 HLA-DRB1 IL10
46 eosinophilic fasciitis 10.2 AHR IFNG
47 idiopathic achalasia 10.2 HLA-DQB1 IL10
48 clonorchiasis 10.2 IFNG IL10
49 pericardial tuberculosis 10.2 IFNG IL10
50 urinary schistosomiasis 10.2 IFNG IL13

Graphical network of the top 20 diseases related to Peanut Allergy:



Diseases related to Peanut Allergy

Symptoms & Phenotypes for Peanut Allergy

MGI Mouse Phenotypes related to Peanut Allergy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.56 AHR CCL22 CD14 CXCL10 HLA-DQB1 IFNG
2 respiratory system MP:0005388 9.1 AHR CD14 HLA-DQB1 IFNG IL10 IL13

Drugs & Therapeutics for Peanut Allergy

Drugs for Peanut Allergy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 61)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Progesterone Approved, Vet_approved Phase 4,Phase 2,Not Applicable 57-83-0 5994
3 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable
4 Progestins Phase 4,Phase 2,Not Applicable
5 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Not Applicable
6 Hormone Antagonists Phase 4,Phase 2,Not Applicable
7 Autonomic Agents Phase 4,Not Applicable
8 Cholinergic Agents Phase 4
9 Central Nervous System Stimulants Phase 4
10 Hormones Phase 4,Phase 2,Not Applicable
11 Nicotinic Agonists Phase 4
12 Peripheral Nervous System Agents Phase 4,Not Applicable
13 Immunoglobulins Phase 3,Phase 1,Phase 2,Not Applicable
14 Immunoglobulin E Phase 3,Phase 1,Phase 2,Not Applicable
15 Antibodies Phase 3,Phase 1,Phase 2,Not Applicable
16 Vaccines Phase 3,Phase 1
17
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
18
Ketotifen Approved Phase 2 34580-14-8, 34580-13-7 3827
19
Omalizumab Approved, Investigational Phase 1, Phase 2,Phase 2 242138-07-4
20
Glycerol Approved, Investigational Phase 1, Phase 2,Phase 2 56-81-5 753
21
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
22
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
23 Estradiol valerate Approved, Investigational, Vet_approved Phase 2 979-32-8
24
Polyestradiol phosphate Approved Phase 2 28014-46-2
25
Benzocaine Approved, Investigational Phase 1, Phase 2,Not Applicable 94-09-7, 1994-09-7 2337
26 tannic acid Approved Phase 1, Phase 2,Not Applicable
27
Histamine Phosphate Phase 2 51-74-1 65513
28 Histamine H1 Antagonists Phase 2
29 Anti-Allergic Agents Phase 2,Phase 1
30 Dermatologic Agents Phase 2
31 Antipruritics Phase 2
32 Histamine Antagonists Phase 2
33 Anti-Asthmatic Agents Phase 1, Phase 2,Phase 2,Not Applicable
34 Respiratory System Agents Phase 1, Phase 2,Phase 2,Not Applicable
35 Protective Agents Phase 1, Phase 2,Phase 2,Not Applicable
36 Immunologic Factors Phase 2,Not Applicable
37 Pharmaceutical Solutions Phase 2,Phase 1,Not Applicable
38 Antibodies, Monoclonal Phase 2
39 Estradiol 3-benzoate Phase 2
40 Contraceptive Agents Phase 2
41
Medroxyprogesterone Phase 2 520-85-4 10631
42 Immune Sera Phase 2
43 Contraceptives, Oral Phase 2
44 Estrogens Phase 2
45 Estradiol 17 beta-cypionate Phase 2
46
Phenol Approved, Experimental Phase 1 108-95-2 996
47
Epinephrine Approved, Vet_approved Not Applicable 51-43-4 5816
48
Racepinephrine Approved Not Applicable 329-65-7 838
49 English walnut Approved ,Not Applicable
50
Nitric Oxide Approved Not Applicable 10102-43-9 145068

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Recruiting NCT01966640 Phase 4
2 Progesterone and Brain Imaging Study Recruiting NCT01954966 Phase 4 Progesterone;Placebo
3 Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers Unknown status NCT02046083 Phase 2, Phase 3 arachid
4 Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Completed NCT02635776 Phase 3
5 Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy Completed NCT02636699 Phase 3
6 Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Completed NCT03126227 Phase 3
7 Peanut Oral Immunotherapy Study of Early Intervention for Desensitization Recruiting NCT03736447 Phase 3
8 Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age Recruiting NCT03211247 Phase 3
9 Safety Study of Viaskin Peanut to Treat Peanut Allergy Active, not recruiting NCT02916446 Phase 3
10 ARTEMIS Peanut Allergy In Children Active, not recruiting NCT03201003 Phase 3
11 PALISADE Follow-on Study (ARC004) Active, not recruiting NCT02993107 Phase 3
12 AR101 Real-World Open-Label Extension Study Active, not recruiting NCT03337542 Phase 3
13 Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children Active, not recruiting NCT03013517 Phase 3 Viaskin Peanut 250µg
14 Long-term Safety Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008) Enrolling by invitation NCT03292484 Phase 3
15 Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents Terminated NCT03703791 Phase 3
16 Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization Unknown status NCT01625715 Phase 2 Ketotifen
17 The Effect of Extrinsic Factors on Food Allergy Unknown status NCT01429896 Phase 2
18 Therapeutic Effect of Chinese Herbal Medicine on Food Allergy Unknown status NCT00602160 Phase 2 FAHF-2 (TM)
19 Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy Completed NCT02920021 Phase 2 ANB020;Placebo
20 Oral Immunotherapy (OIT) for Peanut Allergy Completed NCT00815035 Phase 2 Peanut OIT;Placebo
21 Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy Completed NCT01675882 Phase 2
22 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy Completed NCT01084174 Phase 1, Phase 2 Peanut powder;Peanut extract;Placebo extract;Placebo powder
23 Oral Immunotherapy for Peanut Allergy (PMIT) Completed NCT00597675 Phase 2
24 Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy Completed NCT00932282 Phase 1, Phase 2 Peanut Oral Immunotherapy;Omalizumab
25 Epicutaneous Immunotherapy in Peanut Allergy in Children Completed NCT01197053 Phase 2
26 Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study Completed NCT00932828 Phase 2 Peanut oral immunotherapy
27 Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance Completed NCT01373242 Phase 1, Phase 2 Liquid peanut extract (Peanut SLIT)
28 Omalizumab in the Treatment of Peanut Allergy Completed NCT00949078 Phase 2 omalizumab
29 Xolair Enhances Oral Desensitization in Peanut Allergic Patients Completed NCT01290913 Phase 1, Phase 2 Omalizumab
30 The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery Completed NCT02103270 Phase 2 Peanut Protein 4,000mg;Oat Flour;Peanut Protein 300 mg
31 A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial Completed NCT00580606 Phase 1, Phase 2 Glycerinated peanut allergenic extract;Placebo for peanut extract (glycerin)
32 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial Completed NCT01904604 Phase 2
33 Persistence of Oral Tolerance to Peanut Completed NCT01366846 Phase 2
34 Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children Completed NCT01955109 Phase 2
35 Peanut Oral Immunotherapy in Children Completed NCT01867671 Phase 2
36 Promoting Tolerance to Peanut in High-Risk Children Completed NCT00329784 Phase 2
37 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT Completed NCT01987817 Phase 2
38 Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using (CPNA) Peanut OIT Safety Follow-On Study Completed NCT02198664 Phase 2
39 A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g Completed NCT00382148 Phase 2 omalizumab
40 Mechanisms of Desensitization During Peanut Oral Immunotherapy Completed NCT01814241 Phase 2 Open label peanut OIT
41 A Study of Sublingual Immunotherapy in Peanut-allergic Children Completed NCT00597727 Phase 2 Peanut SLIT;Placebo SLIT
42 Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy) Recruiting NCT03682770 Phase 2 Dupilumab;Placebo matching dupilumab;AR101
43 Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women Recruiting NCT03018366 Phase 2 17beta Estradiol;Transdermal placebo patch;Progesterone;Placebo Pill
44 Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study Active, not recruiting NCT02149719 Phase 2
45 Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy Active, not recruiting NCT02402231 Phase 2 Omalizumab
46 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial Active, not recruiting NCT01781637 Phase 1, Phase 2 Omalizumab;placebo
47 Tolerance Following Peanut Oral Immunotherapy Active, not recruiting NCT01750879 Phase 1, Phase 2 Peanut Flour;Oat Flour
48 FARE Peanut SLIT and Early Tolerance Induction Active, not recruiting NCT02304991 Phase 2 Liquid Peanut Extract;Placebo Glycerin SLIT
49 Salvage Peanut Oral Immunotherapy Study Enrolling by invitation NCT03251508 Phase 1, Phase 2 Peanut OIT
50 Study to Evaluate the Efficacy and Safety of Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy Not yet recruiting NCT03793608 Phase 2 Dupilumab;placebo matching dupilumab

Search NIH Clinical Center for Peanut Allergy

Cochrane evidence based reviews: peanut hypersensitivity

Genetic Tests for Peanut Allergy

Anatomical Context for Peanut Allergy

MalaCards organs/tissues related to Peanut Allergy:

41
Testes, Skin, T Cells, Lung, Bone, Heart, Tongue

Publications for Peanut Allergy

Articles related to Peanut Allergy:

(show top 50) (show all 488)
# Title Authors Year
1
FDA-approved peanut allergy treatment: the first wave is about to crest. ( 29909055 )
2018
2
Single-cell profiling of peanut-responsive T cells in patients with peanut allergy reveals heterogeneous effector T<sub>H</sub>2 subsets. ( 29408715 )
2018
3
Canadian genome-wide association study and meta-analysis confirm HLA as a risk factor for peanut allergy independent of asthma. ( 29325868 )
2018
4
A novel human mast cell activation test for peanut allergy. ( 29731128 )
2018
5
Potential Pitfalls in Applying Screening Criteria in Infants at Risk of Peanut Allergy. ( 29352591 )
2018
6
The Health and Economic Outcomes of Peanut Allergy Management Practices. ( 29751153 )
2018
7
A Mouse Model of Peanut Allergy Induced by Sensitization Through the Gastrointestinal Tract. ( 29956142 )
2018
8
Isotretinoin treatment and peanut allergy: a new case report and review of the literature. ( 29512201 )
2018
9
Peanut Allergy: An Epidemiologic Analysis of a Large Database. ( 29246346 )
2018
10
Nanoemulsion adjuvant-driven redirection of T<sub>H</sub>2 immunity inhibits allergic reactions in murine models of peanut allergy. ( 29655584 )
2018
11
Preventing Peanut Allergy. ( 29588872 )
2018
12
Challenge-confirmed peanut allergy in older patients: Performance of skin tests, specific immunoglobulin E, and ara h 2. ( 29508723 )
2018
13
Role of dendritic cells in peanut allergy. ( 29681186 )
2018
14
The role of environmental exposure to peanut and the development of peanut allergy. ( 29508711 )
2018
15
Should Younger Siblings of Peanut Allergic Children Be Screened for Peanut Allergy? ( 29397371 )
2018
16
Hepatic Mitochondrial Dysfunction and Immune Response in a Murine Model of Peanut Allergy. ( 29890625 )
2018
17
The importance of reducing risk in peanut allergy: Current and future therapies. ( 29289463 )
2018
18
Timely focus on breast-feeding in the peanut allergy debate. ( 29395368 )
2018
19
Peanut allergy reduction in high-risk pediatric patients. ( 29438186 )
2018
20
Preventing peanut allergy in infants: Follow the evidence. ( 29923919 )
2018
21
Understanding Caregiver Goals, Benefits, and Acceptable Risks of Peanut Allergy Therapies. ( 29940310 )
2018
22
Low-dose oral immunotherapy for children with anaphylactic peanut allergy in Japan. ( 29603410 )
2018
23
Oral Immunotherapy in Japanese Children with Anaphylactic Peanut Allergy. ( 29339650 )
2018
24
Peanut Allergy Prevention. ( 29509854 )
2018
25
Cutaneous Sensitization to Peanut in Children With Atopic Dermatitis: A Window to Prevention of Peanut Allergy. ( 30419123 )
2018
26
Updated guidelines on peanut allergy prevention in infants with atopic dermatitis. ( 30063778 )
2018
27
Allergy to Peanuts in Atopic Dermatitis Patients 14 Year or Older and the Association with Food Hypersensitivity, Inhalant Allergens, Asthma Bronchiale and Rhinitis. ( 30078876 )
2018
28
Sensitisation to outdoor and indoor fungi in atopic dermatitis patients and the relation to the occurrence of food allergy to peanuts and walnuts. ( 29772091 )
2018
29
Maternal peanut consumption and risk of peanut allergy in childhood. ( 29986856 )
2018
30
Peanut Allergy: Changes in Dogma and Past, Present, and Future Directions. ( 30001445 )
2018
31
Dietary Supplementation with Nondigestible Oligosaccharides Reduces Allergic Symptoms and Supports Low Dose Oral Immunotherapy in a Peanut Allergy Mouse Model. ( 30102006 )
2018
32
Ratios of specific IgG4 over IgE antibodies do not improve prediction of peanut allergy nor of its severity compared to specific IgE alone. ( 30269403 )
2018
33
Peanut allergy - individual molecules as a key to precision medicine. ( 30281802 )
2018
34
Adjuvanted Immunotherapy Approaches for Peanut Allergy. ( 30319619 )
2018
35
Genetic diversity between mouse strains allows identification of the CC027/GeniUnc strain as an orally reactive model of peanut allergy. ( 30342892 )
2018
36
Ara h 1 and Ara h 6 Sensitization Causes Clinical Peanut Allergy in Ara h 2-Negative Individuals. ( 30368492 )
2018
37
First reported case in Canada of anaphylaxis to lupine in a child with peanut allergy. ( 30386385 )
2018
38
Epicutaneous immunotherapy for peanut allergy modifies IgG4 responses to major peanut allergens. ( 30389411 )
2018
39
Correlation of negative skin-prick test results for tree nuts and successful tree nut challenges among children with peanut allergy. ( 30401323 )
2018
40
Severity of peanut allergy and the unmet gaps in care: a call to action. ( 30427644 )
2018
41
Management of peanut allergy: a focus on novel immunotherapies. ( 30427645 )
2018
42
Cost-effectiveness of diagnostic algorithms for peanut allergy in children. ( 30445059 )
2018
43
Acquired Donor Peanut Allergy From Lung Transplantation Resulting in Respiratory Failure: A Case Report. ( 30447764 )
2018
44
AR101 Oral Immunotherapy for Peanut Allergy. ( 30449234 )
2018
45
Study raises hopes of minimising risk of life threatening peanut allergy reactions. ( 30455358 )
2018
46
Implementation of the NIAID Peanut Allergy Guidelines: Outcomes and Experience. ( 30465858 )
2018
47
Managing Cross-Reactivity in Those with Peanut Allergy. ( 30472327 )
2018
48
Baseline Gastrointestinal Eosinophilia Is Common in Oral Immunotherapy Subjects With IgE-Mediated Peanut Allergy. ( 30524424 )
2018
49
Efficacy and Safety of AR101 in Oral Immunotherapy for Peanut Allergy: Results of ARC001, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. ( 29092786 )
2017
50
Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: The BAMSE population-based birth cohort. ( 28192142 )
2017

Variations for Peanut Allergy

Expression for Peanut Allergy

Search GEO for disease gene expression data for Peanut Allergy.

Pathways for Peanut Allergy

Pathways related to Peanut Allergy according to GeneCards Suite gene sharing:

(show all 33)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 CCL22 CD14 CXCL10 HLA-DQB1 HLA-DRB1 IFNG
2
Show member pathways
13.08 CCL22 CXCL10 HLA-DQB1 HLA-DRB1 IFNG IGHE
3
Show member pathways
12.72 HLA-DQB1 HLA-DRB1 IFNG IL10 IL13
4
Show member pathways
12.64 CXCL10 HLA-DQB1 HLA-DRB1 IFNG IL13
5
Show member pathways
12.48 HLA-DQB1 HLA-DRB1 IFNG IGHE IL10
6
Show member pathways
12.17 AHR HLA-DQB1 HLA-DRB1 IFNG IL10 IL13
7
Show member pathways
12.16 CXCL10 IFNG IL13
8 12.13 CXCL10 HLA-DQB1 HLA-DRB1
9
Show member pathways
12.12 HLA-DQB1 HLA-DRB1 IFNG IL10
10 12.05 CD14 HLA-DQB1 HLA-DRB1 IFNG IL10
11
Show member pathways
12.03 CD14 CXCL10 IFNG
12 11.99 CD14 HLA-DQB1 HLA-DRB1
13
Show member pathways
11.93 CCL22 IFNG IL10 IL13
14
Show member pathways
11.9 CD14 IFNG IL13
15 11.86 CD14 IFNG IL10
16 11.81 CCL22 IGHE IL10 IL13
17 11.77 CD14 HLA-DQB1 HLA-DRB1
18 11.76 CD14 IFNG IL10
19 11.73 HLA-DQB1 HLA-DRB1 IFNG
20 11.64 CD14 IFNG IL10
21 11.64 AHR IFNG IL10 IL13
22 11.49 HLA-DQB1 HLA-DRB1 IL10
23 11.31 CCL22 CXCL10 IL10 IL13
24 11.22 CCL22 IFNG IL10 IL13
25 11.2 IFNG IL10
26 11.2 CD14 IL10
27 11.19 AHR IFNG IL13
28 11.12 HLA-DRB1 IFNG IL13
29 11.07 CCL22 CXCL10 IL10 IL13
30 11.07 IFNG IL10 IL13
31 10.87 CCL22 CXCL10 IFNG IL10 IL13
32 10.85 CCL22 CXCL10 IL10 IL13
33 10.72 HLA-DRB1 IFNG IL10 IL13

GO Terms for Peanut Allergy

Cellular components related to Peanut Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 CCL22 CD14 CXCL10 IFNG IL10 IL13
2 endosome membrane GO:0010008 9.58 CD14 HLA-DQB1 HLA-DRB1
3 extracellular region GO:0005576 9.5 CCL22 CD14 CXCL10 IFNG IGHE IL10
4 clathrin-coated endocytic vesicle membrane GO:0030669 9.37 HLA-DQB1 HLA-DRB1
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.32 HLA-DQB1 HLA-DRB1
6 MHC class II protein complex GO:0042613 9.16 HLA-DQB1 HLA-DRB1
7 external side of plasma membrane GO:0009897 9.02 CD14 CXCL10 HLA-DRB1 IGHE IL13

Biological processes related to Peanut Allergy according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.72 CCL22 CXCL10 IFNG IL10 IL13
2 cellular response to lipopolysaccharide GO:0071222 9.7 CD14 CXCL10 IL10
3 response to virus GO:0009615 9.65 CCL22 CXCL10 IFNG
4 interferon-gamma-mediated signaling pathway GO:0060333 9.61 HLA-DQB1 HLA-DRB1 IFNG
5 negative regulation of endothelial cell apoptotic process GO:2000352 9.58 IL10 IL13
6 negative regulation of interferon-gamma production GO:0032689 9.57 HLA-DRB1 IL10
7 positive regulation of release of sequestered calcium ion into cytosol GO:0051281 9.56 CXCL10 IL13
8 response to lipopolysaccharide GO:0032496 9.56 CD14 CXCL10 IL10 IL13
9 positive regulation of cytokine secretion GO:0050715 9.55 CD14 IL10
10 inflammatory response GO:0006954 9.55 CCL22 CD14 CXCL10 IL10 IL13
11 leukocyte chemotaxis GO:0030595 9.54 CXCL10 IL10
12 positive regulation of macrophage activation GO:0043032 9.51 IL10 IL13
13 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.49 HLA-DQB1 HLA-DRB1
14 response to molecule of bacterial origin GO:0002237 9.46 CD14 IL10
15 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.4 HLA-DQB1 HLA-DRB1
16 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.37 HLA-DQB1 HLA-DRB1
17 cytokine-mediated signaling pathway GO:0019221 9.35 CCL22 CXCL10 IGHE IL10 IL13
18 immune response GO:0006955 9.23 CCL22 CXCL10 HLA-DQB1 HLA-DRB1 IFNG IGHE

Molecular functions related to Peanut Allergy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 9.16 HLA-DQB1 HLA-DRB1
2 cytokine activity GO:0005125 9.02 CCL22 CXCL10 IFNG IL10 IL13
3 MHC class II receptor activity GO:0032395 8.96 HLA-DQB1 HLA-DRB1

Sources for Peanut Allergy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....